Back to Agenda
Session 8: Stakeholder Voice: Biosimilar Decision Making
Session Chair(s)
Laura D. Wingate
Executive Vice President, Education, Support, and Advocacy
Crohn's & Colitis Foundation, United States
Using moderated case presentation learners will explore the decision-making process between a physician and their patient as they determine the best course of biologic/biosimilar treatment. The session will feature three treatment scenarios and discussion:
- Shared decision-making process for a biologic naïve patient
- Discussion between a patient and provider when deciding to switch from a innovator to a biosimilar
- Discussion of the nocebo effect and its impact on decision making and switching behaviors
- Dialogue around multi-switch data and real world experience in practice
Learning Objective : At the conclusion of this session, participants should be able to:
- Understand the factors that influence patient and provider decision as it relates to biosimilars
- Articulate the barriers that are impacting the decision process between patient and provider
- Comprehend the need for to offer biosimilar educational resource for both patients and providers
Speaker(s)
![Francis Farraye, MD, MS](/_Images/member/Generic_Image_Missing-Profile.jpg)
speaker
Francis Farraye, MD, MS
Mayo Clinic Jacksonville, United States
Director, Inflammatory Bowel Disease Center, Professor of Medicine
Speaker
Shubha Bhat, PharmD, MS
Boston Medical Center, Center for Digestive Disorders & Crohn's and Colitis, United States
Ambulatory Care Clinical Pharmacy Specialist - Gastroenterology
![Shaila Abbott](/_Images/member/Generic_Image_Missing-Profile.jpg)
Speaker
Shaila Abbott
Patient Advocate, United States
Speaker
Alex Hochstrasser
Ulcerative Colitis, United States
Patient Advocate
Have an account?